Feasibility of the cardiac output response to stress test in suspected heart failure patients

Sarah J. Charman1,2,3, Nduka C. Okwose1,2,3, Clare J. Taylor4, Kristian Bailey2, Ahmet Fuat5, Arsen Ristic6, Jonathan Mant7, Christi Deaton7, Petar M. Seferovic6, Andrew J.S. Coats8, F.D. Richard Hobbs4, Guy A. MacGowan2,9, Djordje G. Jakovljevic1,2,3,∗

1Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom,
2Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom,
3Research Centre (CSELS), Institute for Health and Wellbeing, Faculty of Health and Life Sciences, Coventry University, and University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom,
4Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, United Kingdom,
5Darlington Memorial Hospital, County Durham and Darlington NHS Foundation Trust & School of Medicine, Pharmacy and Health, Durham University, Durham, United Kingdom,
6Department of Cardiology, Faculty of Medicine, University of Belgrade, Clinical Centre of Serbia, Belgrade, Serbia,
7Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom,
8Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy,
9Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

∗Corresponding author: Cardiovascular Research Division, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Email: djordje.jakovljevic@newcastle.ac.uk

Background: Diagnostic tools available to support general practitioners diagnose heart failure (HF) are limited. 

Objectives: (i) Determine the feasibility of the novel cardiac output response to stress (CORS) test in suspected HF patients, and (ii) Identify differences in the CORS results between (a) confirmed HF patients from non-HF patients, and (b) HF reduced (HFrEF) vs HF preserved (HFpEF) ejection fraction.

Methods: Single centre, prospective, observational, feasibility study. Consecutive patients with suspected HF (N = 105; mean age: 72 ± 10 years) were recruited from specialized HF diagnostic clinics in secondary care. The consultant cardiologist confirmed or refuted a HF diagnosis. The patient completed the CORS but the researcher administering the test was blinded from the diagnosis. The CORS assessed cardiac function (stroke volume index, SVI) noninvasively using the bio-reactance technology at rest-supine, challenge-standing, and stress-step exercise phases.

Results: A total of 38 patients were newly diagnosed with HF (HFrEF, n = 21) with 79% being able to complete all phases of the CORS (91% of non-HF patients). A 17% lower SVI was found in HF compared with non-HF patients at rest-supine (43 ± 15 vs 51 ± 16 mL/beat/m², P = 0.02) and stress-step exercise phase (49 ± 16 vs 58 ± 17 mL/beat/m², P = 0.02). HFrEF patients demonstrated a lower SVI at rest (39 ± 15 vs 48 ± 13 mL/beat/m², P = 0.02) and challenge-standing phase (34 ± 9 vs 42 ± 12 mL/beat/m², P = 0.03) than HFpEF patients.

Conclusion: The CORS is feasible and patients with HF responded differently to non-HF, and HFrEF from HFpEF. These findings provide further evidence for the potential use of the CORS to improve HF diagnostic and referral accuracy in primary care.

Lay summary

Heart failure (HF) is a global pandemic affecting 26 million people worldwide with an estimated 1 million people in the United Kingdom. Accurate early diagnosis of HF and the initiation of evidence-based treatment is essential to reduce morbidity and mortality and the associated burden on healthcare. As there are no state-of-the-art approaches, early diagnosis is challenging and often inaccurate, as initial signs and symptoms are nonspecific. We have developed an innovative test, named CORS (cardiac output response to stress test), to help general practitioners identify HF, which uses a method similar to an electrocardiogram and measures heart function at rest and during short step exercise. We recruited suspected HF patients from specialist HF diagnostic clinics in secondary care to complete the CORS test. We successfully demonstrated that 79% of patients with newly diagnosed HF (n = 38) and 91% of non-HF patients (n = 67) were able to complete all phases of the CORS test. Our findings demonstrate that newly diagnosed HF patients are able to complete this test, which provides further evidence for the potential use of the CORS test to improve HF diagnostic and referral accuracy in primary care.

Key words: cardiac output, feasibility, general practice, heart failure, primary care

Background

Heart failure (HF) is a complex clinical syndrome associated with impaired heart function at rest and/or during exertion.1,2 HF is recognized as a global health and economic burden,3,4 affecting nearly 1 million people in the United Kingdom.1,2,3 HF is a serious chronic disease with poor prognosis, poor quality of life and high healthcare costs.2,6 Five-year mortality rates of nearly 42% are mostly due to
Cardiac output response to stress test

Cardiac output response to stress test

myocardial infarction and worsening HF. The prevalence of HF and consequential hospitalization are expected to rise due to our ageing population affecting ≥10% in individuals >70 years of age.

Typical signs and symptoms of HF include breathlessness, ankle swelling, and fatigue, which are very common and nonspecific. This makes diagnosis challenging due to difficulties in differentiating between HF and other conditions associated with ageing, obesity, or lung disease. In addition, multimorbidity and polypharmacy can complicate the diagnosis further. Early and precise diagnosis of HF is therefore essential in order to apply appropriate treatment, which can improve patient’s morbidity, quality of life, and mortality as well as reducing NHS burden of HF.

Primary care represents an entry point in the clinical care pathway for patients presenting with HF signs and symptoms and general practitioners (GPs) play a key role in identifying HF. Currently, the diagnostic tools available in primary care to help diagnose HF include a full medical history, signs and symptoms, electrocardiography, and serum natriuretic peptides test. However, electrocardiography seems to be an inadequate screening tool for patients with suspected HF as described by a systematic meta-analysis. The serum natriuretic peptides blood test is useful as a “rule out” test but results in a high number of false positives. Furthermore, this diagnostic test continues to be underutilized by GPs in primary care. In practice, all these assessments are used to establish a HF diagnosis, which also therefore requires some specialist clinical interpretation. It is therefore not surprising that current diagnostic practice of HF in primary care results in high number of inaccurate and expensive referrals to secondary care. Diagnostic uncertainty and delayed diagnosis of HF can lead to incorrect treatment, impaired disease progression and increased hospitalization.

The COVID-19 pandemic has further reinforced that new strategies to achieve timely diagnosis due to patients avoiding urgent care for HF signs and symptoms in primary care should be a priority for future research and policy as most recently suggested. To help mitigate this challenge, we have developed and recently confirmed acceptable reproducibility of a novel, easy-to-administer, noninvasive cardiac output response to stress (CORS) test (Fig. 1). Our recent qualitative work with healthcare professionals in primary and secondary care highlighted a high demand for an additional diagnostic tool within primary care to aid diagnostic and referral accuracy. We hypothesis that the CORS test may enable a new clinical pathway—once the serum natriuretic peptides blood test has been reported, GPs would refer patients for the CORS test who demonstrated elevated levels of natriuretic peptides. This has the potential to overcome the reduced specificity of the blood test and improve referral accuracy. The purpose of this present study was: (i) to determine if patients suspected of HF were able to complete the CORS test after being referred to secondary care and (ii) to evaluate differences in the CORS test parameters between HF and non-HF and heart failure reduced (HFpEF) vs heart failure preserved (HFrEF) ejection fraction.

Methods

Study design, setting, and patients

In this single centre, prospective, observational, feasibility study, 105 consecutive suspected HF patients were recruited from HF diagnostic clinics at the Royal Victoria Infirmary, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom. Data were collected between February 2017 and March 2020. Patients aged ≥50 years were included in the study if they were suspected of having HF by their GPs (based on symptoms, signs, physical examination, and raised natriuretic peptides levels) and had been referred to secondary care to a HF diagnostic clinic for specialist review. Signs and symptoms included

Key messages

• Suspected heart failure patients were able to complete the CORS test.
• Different results were found between heart failure and non-heart failure patients.
• Differences were found between ejection fraction groups.

Fig. 1. Timeline of measurements. T1–T4, time points of measurement; LAS, lateral ankle sprain.
breathlessness, ankle swelling, and fatigue, which are found in the ESC HF guidelines.  

Exclusion criteria included a previous diagnosis of HF, the presence of severe symptoms requiring urgent assessment and stabilization, recent acute coronary syndrome and severe physical disability. The study protocol (number 16/NE/0287) was approved by the National Health Service, National Research Authority (North East—Tyne & Wear South Research Ethics Committee). All procedures performed in the study were in accordance with the Declaration of Helsinki. Patients gave written informed consent.

Study protocol and measurements
The CORS test has been described previously.  

It uses continuous haemodynamic measurements based on noninvasive, electrical signal processing bioreactance technology (NICOM, Cheetah Medical, Inc., MA, USA), which we have previously validated. The CORS test has demonstrated acceptable reproducibility in healthy adults (≥50 years old) and consists of 4 phases: (i) rest (patients lies in the supine position for 3 min); (ii) challenge (patients remains in the standing position for 3 min); (iii) and (iv) stress-step exercise (patient completes a step test on a 15-inch step board with intensity controlled by a metronome at 10 and 15 steps per min). Due to time restrictions in the clinic, patients in this study only completed 1 stress-step exercise phase at the 15 steps per min intensity.

Suspected HF patient NTproBNP (ng/L) levels were recorded from patient records, which the consultant cardiologist would extract as part of the diagnostic tests to confirm or refute a diagnosis of HF. NICE guidelines recommend referral to specialist assessment and echocardiography when NTproBNP levels are between 400 and 2,000 ng/L within 6 weeks whereas levels >2,000 ng/L require referral within 2 weeks. Patients completed a number of diagnostic tests including echocardiography (estimated left ventricular ejection fraction, LVEF %) and electrocardiography, and were seen by a consultant cardiologist—HF specialist who reviewed their medical history, diagnostic test results, and conducted a physical examination to confirm or rule out a diagnosis of HF. The consultant cardiologist confirmed a diagnosis of HFpEF by estimated LVEF <40% or HFrEF by estimated LVEF ≥50%. There were 6 patients diagnosed with HF with midrange ejection (HFmrEF) who were grouped with HFrEF for the purposes of this study. All CORS test assessments for this study were administered by a researcher and completed after the patient had been seen by the consultant cardiologist and a diagnosis of HF was confirmed or refuted. The researcher was blinded from echocardiology and patient diagnosis at the time of conducting the CORS test.

Statistical analysis
Data were analysed using SPSS, version 25 (SPSS, Inc., Chicago, IL, USA). The level of significance was set at P <0.05. Data are expressed as mean ± SD unless otherwise indicated. Prior to statistical analysis, data were screened for univariate outliers using standard Z-distribution cut-offs. Shapiro–Wilk test was used to assess normality of distribution and Levene’s test confirmed homogeneity of variances. Differences between the 2 groups (confirmed HF and non-HF patients) were assessed using either an independent t-test or Mann–Whitney U test. In a separate subset analysis, confirmed HF patients only were grouped by ejection fraction diagnosis (HFrEF vs HFpEF) and differences were assessed using either an independent t-test or Mann–Whitney U test.

Results
Patients’ demographics, clinical characteristics, and medication list are presented in Table 1. Confirmed HF patients had a significantly lower estimated LVEF % (43 ± 12% vs 54 ± 4%, P < 0.01) and higher NTproBNP (1,883 ± 1,957 vs 748 ± 910 ng/L, P < 0.01) than non-HF patients. There were no other significant differences between the groups in their demographic and clinical characteristics. All patients completed the rest phase of the CORS test (38 with HF and 67 without HF). While all confirmed HF patients were able to complete the challenge phase, this was the case for 93% of non-HF cases. A total of 79% of newly diagnosed HF patients completed all 3 phases of the CORS test, including the stress-step exercise, whereas 91% of non-HF patients completed all 3 phases of the CORS test. The reasons for missing measurements varied. The consultant cardiologist requested that the patient not complete either the challenge-standing (non-HF patients, n = 1) and/or the stress-step exercise (confirmed HF patients, n = 4; non-HF patients, n = 2) phases due to their condition or there was poor connectivity and signal loss during measurements (challenge-standing phase: non-HF patients, n = 4; stress-step exercise phase: confirmed HF patients, n = 2; non-HF patients, n = 3) or the patient reported balance issues for the stress-step exercise phase and researcher did not complete this phase (confirmed HF patients, n = 2; non-HF patients, n = 1). For the challenge-standing and stress-step exercise phases that included complete patient haemodynamic measurements but resulted in missing blood pressure measurements were due to poor connectivity or system time out from the bioreactance technology as the patient was not seated at the time of these phase measurements (missing blood pressure measurements: 5% for challenge-standing phase for confirmed HF patients, n = 2/38; 23% for stress-step exercise phase for both confirmed HF patients, n = 7/30 and non-HF patients, n = 14/61).

Table 2 displays the haemodynamic variables for patients with confirmed HF and non-HF for the 3 phases of the CORS test (rest, challenge, and stress-step exercise). At rest, patients with confirmed HF had a significantly higher heart rate (74 ± 16 vs 68 ± 16 beats/min, P = 0.03), lower stroke volume (84 ± 28 vs 97 ± 33 mL/beat, P = 0.04), lower stroke volume index (SVI; 43 ± 15 vs 51 ± 16 mL/beat/m², P = 0.02), and higher diastolic blood pressure (85 ± 12 vs 80 ± 11 mm Hg, P = 0.02) than non-HF patients.

For the challenge phase of the CORS test, heart rate was significantly higher in the confirmed HF patients (81 ± 18 vs 72 ± 14 beats/min, P = 0.01) but no other variables were significantly different between confirmed HF and non-HF. Patients with confirmed HF had a significantly lower SVI compared with the non-HF group for the stress-step exercise phase of the CORS test (49 ± 16 vs 58 ± 17, mL/beat/m², P = 0.02).

In the subset analysis of confirmed HF patients only, there were 21 HFrEF (males, n = 15, females, n = 6; LVEF = 35 ± 10%) patients and 17 (males, n = 11, females, n = 6; LVEF = 53 ± 3%) HFpEF patients. Patients with HFpEF were significantly older than patients with HFrEF (81 ± 7 vs
68 ± 11 years old, \( P < 0.01 \) No significant differences were found between patients with HFrEF and HFpEF for body mass index (31 ± 7 vs 30 ± 5 kg/m², \( P = 0.63 \)) and NTproBNP (1,851 ± 2,547 vs 1,909 ± 1,478 ng/L, \( P = 0.95 \)). Table 3 shows the haemodynamic variables for both HFrEF and HFpEF patients for the 3 phases of the CORS test (rest, challenge, and stress-step exercise). At all 3 phases of the CORS test, patients with HFrEF had significantly higher heart rate (80 ± 18 vs 67 ± 11 beats/min, \( P = 0.02 \); 88 ± 20 vs 73 ± 12 beats/min, \( P = 0.01 \); and 106 ± 22 vs 91 ± 24 beats/min, \( P = 0.04 \)) compared with patients with HFpEF. SVI was significantly lower in patients with HFrEF at the rest and challenge phases (39 ± 15 vs 48 ± 13 mL/beat/m², \( P = 0.02 \) and 34 ± 9 vs 42 ± 12 mL/beat/m², \( P = 0.03 \), respectively) than patients with HFpEF. Systolic blood pressure was lower in patients with HFrEF at the challenge phase compared with patients with HFpEF (132 ± 20 vs 147 ± 22 mm Hg, \( P = 0.05 \)). No other significant differences were found between the 2 groups.

**Discussion**

The purpose of the present study was to determine the feasibility for completing the CORS test in suspected HF patients and to evaluate the differences in the CORS test parameters between HF and non-HF and patients with HFrEF and HFpEF. The preliminary findings highlight that nearly 80% of newly diagnosed HF patients were able to successfully complete all phases of the CORS test (including step exercise). There were differences in haemodynamic function between confirmed HF and non-HF patients at each of the phases of the CORS test. There were further differences between patients with HFrEF and those with a diagnosis of HFpEF.

The ESC HF guidelines defines HF as a clinical syndrome associated with cardiac functional and/or structural abnormalities resulting in reduced cardiac output at rest and/or during stress.1 However, in the description of diagnostic pathway there is no indication about monitoring and reporting haemodynamic measurements in patients undergoing HF diagnostic

**Table 1.** Patient demographics, cardiovascular comorbidities, and medications (February 2017–March 2020).

|                   | Confirmed HF | Non-HF | \( P \) |
|-------------------|--------------|--------|--------|
| Age (years)       | 73 ± 12      | 71 ± 9 | 0.29   |
| Gender, male/female | 26/12       | 31/36  |        |
| Height (cm)       | 170 ± 7      | 168 ± 10 | 0.26   |
| Body weight (kg)  | 89 ± 21      | 87 ± 22 | 0.55   |
| Body mass index (kg/m²) | 31 ± 6    | 31 ± 7  | 0.89   |
| LVEF (%)          | 43 ± 12      | 54 ± 4  | 0.00   |
| NTproBNP (ng/L)   | 1,883 ± 1,957 | 748 ± 910 | 0.00   |

Cardiovascular comorbidities (%)\(^a\)

- Atrial fibrillation: 47 (18, 29) vs 24
- Ischaemic heart disease: 21 (11, 11) vs 9
- Dilated cardiomyopathy: 8 (8, 0) vs 0
- Coronary heart disease: 16 (11, 5) vs 9
- Coronary artery bypass graft: 3 (3, 0) vs 0
- Myocardial infarction: 16 (13, 3) vs 4
- Hypertension: 8 (3, 5) vs 0
- Atrial dysrhythmia: 3 (0, 3) vs 0
- Pulmonary hypertension: 3 (0, 3) vs 1

Medications (%)\(^a\)

- Angiotensin-converting enzyme inhibitors: 53 (32, 21) vs 33
- Angiotensin II receptor antagonist: 24 (11, 13) vs 16
- Beta-adrenergic blocker: 63 (37, 26) vs 46
- Calcium channel blocker: 16 (3, 13) vs 7
- Diuretics: 71 (39, 32) vs 30
- Anti-arrhythmia: 42 (13, 29) vs 37
- Anti-anginal: 3 (0, 3) vs 9
- Diabetes: 13 (11, 3) vs 21
- Corticosteroids: 0 (0, 0) vs 7
- Anti-inflammatory: 0 (0, 0) vs 10
- Antidepressant: 24 (16, 8) vs 27
- Statins: 66 (32, 34) vs 66
- Anticoagulants: 47 (24, 24) vs 33

Data are expressed as mean ± SD.
\(^a\)% data are reported in brackets for HFrEF and HFpEF patients.
clinical investigation. Thus, we have developed the CORS test to evaluate whether monitoring haemodynamics in patients with suspected HF at rest and in response to stress, using a simple and noninvasive technology, may help primary care physicians to more accurately rule-in or rule-out HF in conjunction with other accessible investigations including medical history, physical examination, electrocardiogram, and natriuretic peptide test. Primary care is recognized as a key area to develop new strategies to achieve timely HF diagnosis and in this study the CORS test has demonstrated some important findings in newly diagnosed HF patients.

The present study reveals that the majority of patients were able to complete all phases of the CORS test (rest-supine, challenge-standing, and stress-step exercise). This was a concern raised by healthcare professionals during our qualitative evaluation of the potential implementation of the CORS test for suspected HF in primary care. The CORS test was administered in 18 ± 3 min so an additional appointment will be required for this test to be included within primary care. The qualitative work highlighted that not all phases of the test would be suitable for all patients. This current study has seen adaptations to the CORS test such as reducing the 2-phase stress-step exercise (originally proposed) to 1 phase to be time efficient and using a balance aid for the stress-step exercise phase when the patient required, which are important developments if as suggested from our qualitative work that either a practice nurse or healthcare assistant would be able to deliver the test within a primary care setting. Using such approach we achieved a 93% and 79% success rate for completion of the stress-exercise CORS test in patients with suspected HF and those with confirmed HF. This finding addresses previous concerns identified in our qualitative work by GPs and practice nurses that completion of the CORS test will be achieved in only 50%–80% of patients. It should also be noted that haemodynamic measurements during the rest phase of the CORS test could be achieved in all patients, and can yield important information about the presence and type of HF, as described below.

In patients with confirmed HF, heart rate was significantly higher at both rest and challenge phases compared with non-HF patients. Likewise, for all 3 phases of the CORS test, heart rate was higher in patients with HFrEF compared with patients with HFpEF. In patients with HFrEF, findings highlight that for every beat increase in heart rate, there is a 3% increase in risk of mortality or hospital admission for worsening HF. Heart rate control is a vital part of HF management. As the patients in our study were recruited from a diagnostic clinic, this was before treatment optimization. Both the rest and stress-step exercise phases resulted in a lower stroke volume and/or SVI for confirmed HF patients.

### Table 2. Haemodynamic measures for confirmed and non-HF patients for all phases of the CORS test (February 2017–March 2020).

| Phase | Confirmed HF patients | N | Non-HF patients | N | % difference | P  |
|-------|----------------------|---|----------------|---|-------------|----|
| Phase 1—rest | | | | | | |
| QT (L/min) | 6.0 ± 1.5 | 38 | 6.3 ± 1.8 | 67 | 5 | 0.37 |
| CI (L/min/m²) | 3.0 ± 0.8 | 38 | 3.3 ± 0.8 | 67 | 10 | 0.15 |
| HR (beats/min) | 74 ± 16 | 38 | 68 ± 16 | 67 | 8 | 0.03 |
| SV (mL/beat) | 84 ± 28 | 38 | 97 ± 33 | 67 | 14 | 0.04 |
| S VI (mL/beat/m²) | 43 ± 15 | 38 | 51 ± 16 | 67 | 17 | 0.02 |
| SBP (mm Hg) | 143 ± 25 | 38 | 143 ± 21 | 67 | 0 | 0.84 |
| MAP (mm Hg) | 104 ± 13 | 38 | 101 ± 12 | 67 | 3 | 0.25 |
| Phase 2—challenge | | | | | | |
| QT (L/min) | 5.7 ± 1.3 | 38 | 5.6 ± 1.6 | 62 | 2 | 0.43 |
| CI (L/min/m²) | 2.9 ± 0.7 | 38 | 2.9 ± 0.7 | 62 | 0 | 0.8 |
| HR (beats/min) | 81 ± 18 | 38 | 72 ± 14 | 62 | 12 | 0.01 |
| SV (mL/beat) | 73 ± 21 | 38 | 79 ± 24 | 62 | 8 | 0.35 |
| S VI (mL/beat/m²) | 38 ± 11 | 38 | 41 ± 11 | 62 | 8 | 0.18 |
| SBP (mm Hg) | 138 ± 22 | 36 | 144 ± 22 | 62 | 4 | 0.19 |
| DBP (mm Hg) | 83 ± 11 | 36 | 83 ± 12 | 62 | 0 | 0.74 |
| MAP (mm Hg) | 102 ± 12 | 36 | 104 ± 14 | 62 | 2 | 0.44 |
| Phase 3—stress-step exercise | | | | | | |
| QT (L/min) | 9.4 ± 3.3 | 30 | 10.4 ± 3.7 | 61 | 10 | 0.23 |
| CI (L/min/m²) | 4.8 ± 1.5 | 30 | 5.5 ± 1.8 | 61 | 14 | 0.12 |
| HR (beats/min) | 100 ± 24 | 30 | 93 ± 16 | 61 | 7 | 0.36 |
| SV (mL/beat) | 96 ± 32 | 30 | 113 ± 37 | 61 | 16 | 0.04 |
| S VI (mL/beat/m²) | 49 ± 16 | 30 | 58 ± 17 | 61 | 17 | 0.02 |
| SBP (mm Hg) | 150 ± 30 | 23 | 150 ± 26 | 47 | 0 | 0.93 |
| DBP (mm Hg) | 91 ± 13 | 23 | 92 ± 17 | 47 | 1 | 0.71 |
| MAP (mm Hg) | 110 ± 18 | 23 | 112 ± 18 | 47 | 2 | 0.69 |

Cl, cardiac index; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; QT, cardiac output; SBP, systolic blood pressure; SV, stroke volume. Data are expressed as mean ± SD.
compared with non-HF patients. The differences in the subset analysis of confirmed HF patients revealed differences in SVI at the rest and challenge phases of the CORS test with lower readings for patients with HFrEF vs patients with HFpEF. Lower stroke volume has been reported previously in patients with HFrEF at rest and at exercise compared with patients with HFpEF.\(^{33}\) Similarly, lower SVI has been found at rest in patients with HFrEF \((n = 157)\) compared with healthy participants \((n = 147)\) using cardiovascular magnetic resonance.\(^{34}\)

Diastolic blood pressure was significantly different at rest with a higher reading recorded in the confirmed HF group vs non-HF group. No other significant blood pressure differences were recorded between groups. Although, in the subset analysis, systolic blood pressure was lower in the HFrEF group at the challenge phase compared with the HFpEF group. Interestingly, in the confirmed HF group, systolic and diastolic blood pressure decreased from supine to challenge phases. Abnormal haemodynamic postural response differences have been found previously in HF patients with lower blood pressure recorded at a standing position vs supine, which may present as postural hypotension.\(^{35}\)

For the first time, we have provided results from suspected HF patients completing the CORS test. However, this study is not without limitations. This was a single centre, prospective observational, feasibility study with moderate sample size.

Our ongoing research programme aims to confirm the diagnostic accuracy (sensitivity and specificity) of the CORS test with the objective of its implementation in primary care to improve diagnosis of HF. Although at the time of performing the CORS test, all patients were suspected of having HF, Table 1 shows differences in medication used at the time of investigations, which may influence haemodynamic function. We acknowledge that at the point of HF diagnosis that medication was not titrated. We did not use a visual analogue scale to assess patient burden of completing the CORS test, which would have strengthened our feasibility findings. The patient was not blinded from their diagnosis at the time of completing the CORS test and we acknowledge that this may have impacted on their well-being and capacity to perform the test. The patients were seen by one of 3 consultant cardiologists (HF specialists), however, we did not complete inter-rater variability between the clinicians regarding HF diagnosis.

The major findings of the present study highlight that the CORS test can be completed by the majority of patients undergoing a clinical investigation for a diagnosis of HF within a secondary care setting. The findings have shown that performing the CORS test in HF suspected patients is feasible within a secondary care setting. Furthermore study results demonstrate haemodynamic differences between HF and non-HF as well as HFrEF vs HFpEF. It appears that SVI

### Table 3. Haemodynamic measures for confirmed HF patients for all phases of the CORS test (February 2017–March 2020).

| Phase 1—rest | HFrEF | N | HFpEF | N | % difference | P |
|-------------|-------|---|-------|---|--------------|---|
| QT (L/min)  | 6.0 ± 1.6 | 21 | 6.0 ± 1.3 | 17 | 0 | 0.92 |
| CI (L/min/m²) | 3.0 ± 0.8 | 21 | 3.1 ± 0.7 | 17 | 3 | 0.57 |
| HR (beats/min) | 80 ± 18 | 21 | 67 ± 11 | 17 | 18 | 0.02 |
| SV (mL/beat) | 78 ± 27 | 21 | 92 ± 29 | 17 | 16 | 0.15 |
| S VI (mL/beat/m²) | 39 ± 15 | 21 | 48 ± 13 | 17 | 21 | 0.02 |
| SBP (mm Hg) | 135 ± 23 | 21 | 151 ± 25 | 17 | 11 | 0.09 |
| DBP (mm Hg) | 87 ± 11 | 21 | 82 ± 12 | 17 | 6 | 0.23 |
| MAP (mm Hg) | 103 ± 14 | 21 | 105 ± 13 | 17 | 2 | 0.69 |

| Phase 2—challenge | HFrEF | N | HFpEF | N | % difference | P |
|-------------------|-------|---|-------|---|--------------|---|
| QT (L/min)  | 5.6 ± 1.3 | 21 | 5.7 ± 1.4 | 17 | 2 | 0.67 |
| CI (L/min/m²) | 2.8 ± 0.7 | 21 | 3.0 ± 0.8 | 17 | 7 | 0.44 |
| HR (beats/min) | 88 ± 20 | 21 | 73 ± 12 | 17 | 19 | 0.01 |
| SV (mL/beat) | 67 ± 16 | 21 | 81 ± 24 | 17 | 19 | 0.05 |
| S VI (mL/beat/m²) | 34 ± 9 | 21 | 42 ± 12 | 17 | 21 | 0.03 |
| SBP (mm Hg) | 132 ± 20 | 21 | 147 ± 22 | 15 | 11 | 0.05 |
| DBP (mm Hg) | 85 ± 12 | 21 | 81 ± 11 | 15 | 5 | 0.37 |
| MAP (mm Hg) | 101 ± 13 | 21 | 103 ± 11 | 15 | 2 | 0.57 |

| Phase 3—stress-step exercise | HFrEF | N | HFpEF | N | % difference | P |
|-----------------------------|-------|---|-------|---|--------------|---|
| QT (L/min)  | 9.5 ± 3.5 | 17 | 9.2 ± 3.3 | 13 | 3 | 0.71 |
| CI (L/min/m²) | 4.7 ± 1.5 | 17 | 4.8 ± 1.6 | 13 | 2 | 0.93 |
| HR (beats/min) | 106 ± 22 | 17 | 91 ± 24 | 13 | 15 | 0.04 |
| SV (mL/beat) | 90 ± 31 | 17 | 103 ± 33 | 13 | 13 | 0.28 |
| S VI (mL/beat/m²) | 46 ± 16 | 17 | 54 ± 16 | 13 | 16 | 0.18 |
| SBP (mm Hg) | 141 ± 27 | 13 | 162 ± 29 | 10 | 14 | 0.09 |
| DBP (mm Hg) | 88 ± 12 | 13 | 93 ± 15 | 10 | 6 | 0.38 |
| MAP (mm Hg) | 105 ± 17 | 13 | 116 ± 17 | 10 | 10 | 0.14 |

CI, cardiac index; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; QT, cardiac output; SBP, systolic blood pressure; SV, stroke volume. Data are expressed as mean ± SD.
at rest and its response to challenge (standing) and/or short step exercise differentiate the most between patients with HF from non-HF patients and HFpEF from HFrEF. Our ongoing research will define cut-off values for the CORS test variables and confirm their sensitivity and specificity to complement diagnosis of HF in primary care.

Funding
This study was funded by the UK Medical Research Council Confidence in Concept Scheme grant to DGJ (BH161161). At the time of the study DGJ was supported by the UK Research Councils’ Newcastle Centre for Ageing and Vitality (L016354). SJC, NCO, GAM, and DGJ are supported by the European Horizon 2020 Research and Innovation programme under the grant agreement number 777204. The views expressed are those of the authors and not necessarily those of the Medical Research Council. CJT is a NIHR Academic Clinical Lecturer. FDRH acknowledges support from the NIHR School for Primary Care Research, NIHR CLAHRC Oxford, the NIHR Oxford BRC, and Harris Manchester College, Oxford. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The funders of the study had no role in study design or in data collection, analysis, or interpretation.

Ethical approval
The study protocol (number 16/NE/0287) was approved by the National Health Service, National Research Authority (North East—Tyne & Wear South Research Ethics Committee).

Conflict of interest
CJT reports personal fees from Vifor and Novartis and nonfinancial support from Roche outside the submitted work. FDRH reports personal fees and other from Boehringer Ingelheim and grants from Pfizer outside the submitted work. The other authors declare no conflict of interests.

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.

References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
2. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. 2018.
3. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–1133.
4. Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, Salimi-Khorshidi G, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiol. 2019;4(11):1102–1111.
5. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–580.
6. Taylor CJ, Ryan R, Nichols L, Gale N, Hobbs FR, Marshall T. Survival following a diagnosis of heart failure in primary care. Fam Pract. 2017;34(2):161–168.
7. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J. 2007;28(9):1128–1134.
8. National Institute for Health and Clinical Excellence. Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care. 2010.
9. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13(32):1–207.
10. Taylor CJ. Diagnosing heart failure: challenges in primary care. Heart. 2019;105(9):663–664.
11. Hobbs FD, Doust J, Mant J, Cowie MR. Heart failure: diagnosis of heart failure in primary care. Heart. 2010;96(21):1773–1777.
12. British Society for Heart Failure. National Heart Failure Audit 2016–2017 summary report. 2018.
13. Taylor CJ, Rutten FH, Brouwer JR, Hobbs FR. Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations. Br J Gen Pract. 2017;67(660):326–327.
14. Roalfe AK, Mant J, Doust JA, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, et al. Development and initial validation of a simple clinical decision tool to predict the presence of heart failure in primary care: the MICE (Male, Infarction, Crepitations, Edema) rule. Eur J Heart Fail. 2012;14(9):1000–1008.
15. Khunti K, Squire I, Abrams KR, Sutton AJ. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail. 2004;6(5):571–576.
16. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004;164(18):1978–1984.
17. Roberts E, Ludman AJ, Dzworynski K, Al-Mohammad A, Cowie MR, McMurray JJ, Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h3910.
18. Taylor CJ, Roalfe AK, Iles R, Hobbs FR, Barton P, Deeks J, Mccahon D, Cowie MR, Sutton G, Davis RC, et al. Primary care REFerral for Echocardiography (REFER) in heart failure: a diagnostic accuracy study. Br J Gen Pract. 2017;67(655):e94–e102.
19. Valk M, Hoes AW, Mosterd A, Broekhuizen B, Zuihoff N, Rutten FH. Time trends in the use and appropriateness of natriuretic peptide testing in primary care: an observational study. BJGP Open. 2020;4(4):bjgpopen20X101074.
20. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865–2873.
21. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11(2):95–107.
22. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. *BMJ*. 2003;326(7382):196.

23. Moayedi Y, Alba AC, Lee DS, Wijeysundera HC, Ross HJ. The next wave of health care strain related to COVID-19: heart failure patients coming back in force: we must not fail them. *Can J Cardiol*. 2020;36(7):993–994.

24. George I, Salma M, Kobsa S, Deroo S, Krieger J, Blitzer D, Shea NJ, D’Angelo A, Raza T, Kurlansky P, et al. The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: insights and clinical strategies from a centre at the epicentre. *Eur J Cardiothorac Surg*. 2020;58(4):667–675.

25. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. *BMJ*. 2019;364:l223.

26. Charman SJ, Okwose NC, Stefanetti RJ, Bailey K, Skinner J, Ristic A, Seferovic PM, Scott M, Turley S, Fuat A, et al. A novel cardiac output response to stress test developed to improve diagnosis and monitoring of heart failure in primary care. *ESC Heart Fail*. 2018;5(4):703–712.

27. Charman S, Okwose N, Maniatopoulos G, Grazioso S, Metzler T, Banks H, Vale L, MacGowan GA, Seferović PM, Fuat A, et al. Opportunities and challenges of a novel cardiac output response to stress (CORS) test to enhance diagnosis of heart failure in primary care: qualitative study. *BMJ Open*. 2019;9(4):e028122.

28. Perkins RE, Hollingsworth KG, Eggett C, MacGowan GA, Bates MG, Treneil MI, Jakovljevic DG. Relationship between bioreactance and magnetic resonance imaging stroke volumes. *Br J Anaesth*. 2016;117(1):134–136.

29. Jones TW, Houghton D, Cassidy S, MacGowan GA, Trenell MI, Jakovljevic DG. Bioreactance is a reliable method for estimating cardiac output at rest and during exercise. *Br J Anaesth*. 2015;115(3):386–391.

30. Jakovljevic DG, Treneil MI, MacGowan GA. Bioimpedance and bioreactance methods for monitoring cardiac output. *Best Pract Res Clin Anaesthesiol*. 2014;28(4):381–394.

31. Böh m M, Swedberg K, Komajda M, Bor rer JS, Ford I, Dub ost-Brama A, Lerebours G, Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. *Lancet*. 2010;376(9744):886–894.

32. Fu M, Ahrenmark U, Ber glund S, Lindholm CJ, Lehto A, Broberg AM, Tasevska-Dinevska G, Wikstrom G, Ågard A, Andersson B, et al. Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). *Clin Res Cardiol*. 2017;106(12):960–973.

33. Tsujinaga S, Iwano H, Chiba Y, Ishizaka S, Sarashina M, Murayama M, Nakabachi M, Nishino H, Yokoyama S, Okada K, et al. Heart failure with preserved ejection fraction vs. reduced ejection fraction—mechanisms of ventilatory inefficiency during exercise in heart failure. *Circ Rep*. 2020;2(5):271–279.

34. Carlsson M, Andersson R, Bloch KM, Steding-Ehrenborg K, Mosén H, Stahlberg F, Ekmeahag B, Arheden H. Cardiac output and cardiac index measured with cardiovascular magnetic resonance in healthy subjects, elite athletes and patients with congestive heart failure. *J Cardiovasc Magn Reson*. 2012;14(1):51.

35. Bronzwaer, T, Bogert LWJ, Westerhof BE, Piek JJ, Daemen MJAP, van Lieshout JJ. Abnormal haemodynamic postural response in patients with chronic heart failure. *ESC Heart Fail*. 2017;4(2):146–153.